A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

BMC Public Health

Cecine N Nguyen¹  Ashley JR Carter¹ 

[1] Biological Sciences Department, California State University Long Beach, 1250 Bellflower Blvd, Long Beach, CA, 90840, USA

关键词: Economic cost;    Burden;    DALY;    Disability adjusted life years;    YLL;    Years of life lost;    Research funding;    Cancer;   

Others  :  1163449
DOI  :  10.1186/1471-2458-12-526

 received in 2012-03-08, accepted in 2012-07-17,  发布年份 2012

【 摘 要 】

Background

Ideally, the distribution of research funding for different types of cancer should be equitable with respect to the societal burden each type of cancer imposes. These burdens can be estimated in a variety of ways; “Years of Life Lost” (YLL) measures the severity of death in regard to the age it occurs, "Disability-Adjusted Life-Years" (DALY) estimates the effects of non-lethal disabilities incurred by disease and economic metrics focus on the losses to tax revenue, productivity or direct medical expenses. We compared research funding from the National Cancer Institute (NCI) to a variety of burden metrics for the most common types of cancer to identify mismatches between spending and societal burden.

Methods

Research funding levels were obtained from the NCI website and information for societal health and economic burdens were collected from government databases and published reports. We calculated the funding levels per unit burden for a wide range of different cancers and burden metrics and compared these values to identify discrepancies.

Results

Our analysis reveals a considerable mismatch between funding levels and burden. Some cancers are funded at levels far higher than their relative burden suggests (breast cancer, prostate cancer, and leukemia) while other cancers appear underfunded (bladder, esophageal, liver, oral, pancreatic, stomach, and uterine cancers).

Conclusions

These discrepancies indicate that an improved method of health care research funding allocation should be investigated to better match funding levels to societal burden.

【 授权许可】

   
2012 Carter and Nguyen; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Jemal A, Siegel R, Jiaquan X, Ward E: Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60:277-300.
• [2]Gross CP, Anderson GF, Powe NR: The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999, 340(24):1881-1887.
• [3]Gardner JW, Sanborn JS: Years of potential life lost (YPLL)–what does it measure? Epidemiology 1990, 1(4):322-329.
• [4]Murphy SL, Xu J, Kochanek KD: Deaths: Preliminary Data for. Natl Vital Stat Rep 2010, 60(4):51.
• [5]Nahin RL: Identifying and pursuing research priorities at the National Center for Complementary and Alternative Medicine. FASEB J 2005, 19:1209-1215.
• [6]Gouda HN, Powles JW: Why my disease is important: metrics of disease occurrence used in the introductory sections of papers in three leading general medical journals in 1993 and 2003. Population Health Metrics 2011, 9:14. BioMed Central Full Text
• [7]Gillum LA, Gouveia C, Dorsey ER, Pletcher M, Mathers CD, McCulloch CE, Johnston SC: NIH disease funding levels and burden of disease. PLoS One 2011, 6(2):e16837.
• [8]Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP: Years of life lost (YLL) from cancer is an important measure of population burden - and should be considered when allocating research funds. Br J Cancer 2005, 92(2):241-255.
• [9]Mitchell RJ, McClure RJ, Olivier J, Watson WL: Rational allocation of Australia's research dollars: does the distribution of NHMRC funding by National Health Priority Area reflect actual disease burden? Medical Journal of Australia 2009, 191(11–12):648-652.
• [10]Cancer Australia: Cancer research in Australia: An overview of cancer research projects and research programs in Australia 2003 to 2005. Canberra. 2007.
• [11]Shirazee N, Musiello T, Johnson C, Saunders C: Cancer research and funding in Western Australia: an overview from 2008 to 2010. CancerForum 2011, 35(3):195-200.
• [12]Catalá López F, Alvarez Martín E, Gènova Maleras R, Morant Ginestar C: Relationship between Research Funding in the Spanish National Health System and the Burden of Disease. Rev Esp Salud Publica 2009, 83(1)):137-151.
• [13]Dorsey ER, Thompson JP, Carrasco M, de Roulet J, Vitticore P, Nicholson S, Johnston SC, Holloway RG, Moses H: Financing of U.S. biomedical research and new drug approvals across therapeutic areas. PLoS One 2009, 4(9):e7015.
• [14]Luengo-Fernandez R, Leal J, Gray AM: UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden? Eur J Neurol 2012, 19:149-154.
• [15]Branton PE: Does Canadian research investment relate to cancer burden? Lancet Oncol 2008, 9(2):82-83.
• [16]Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (Eds): SEER Cancer Statistics Review. National Cancer Institute,  ; 1975–2007. http://seer.cancer.gov/csr/1975_2007/ webcite
• [17]Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML: Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008, 100(9):630-641.
• [18]World Health Organization: The global burden of disease: 2004 update. Geneva. 2008.
• [19] : FY2010 Funding by Cancer Type. http://fundedresearch.cancer.gov/ webcite
• [20]Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ: Estimates and projections of value of life lost from cancer deaths in the U.S. J Natl Cancer Inst 2008b, 100(24):1755-1762.
• [21]Costs of Cancer Care: Cancer Trends Progress Report - 2009/2010. http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2007&chid=75&coid=726&mid webcite
• [22]Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML: Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 2008, 100(24):1763-1770.
• [23]USEPA: Guidelines for Preparing Economic Analyses. EPA-240-R-00-003,  ; 2009. 1636. http://yosemite.epa.gov/ee/epa/eed.nsf/pages/Guidelines.html webcite
• [24]Miller TR, Brinkman CP, Stephen L: Crash Costs and Safety Investment. In Proceedings of the 32nd Annual Conference, Association for the Advancement of Automotive Medicine. Federal Highway Administration Fact Sheet T7570.2, Des Plaines, IL; 1988. http://safety.fhwa.dot.gov/facts_stats/t75702.cfm webcite
• [25]McKenna MT, Michaud CM, Murray CJL, Marks JS: Assessing the Burden of Disease in the United States Using Disability-Adjusted Life Years. Am J Prev Med 2005, 25(5):415-423.
• [26]Arnesen T, Nord E: The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ 2005, 319:1423-1425.
• [27]National Cancer Research Institute: Strategic Analysis 2002 An Overview of Cancer Research in the UK Directly Funded by the NCRI Partner Organizations. London.  ,  ; 2002.
• [28]Kolata G: Grant system leads cancer researchers to play it safe. , New York Times; 2009. June 27